The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
Open accessAbstract
Controlling the biodistribution of nanoparticles upon intravenous injection is the key to achieving target specificity. One of the impediments in nanoparticle-based tumor targeting is the inability to limit the trafficking of nanoparticles to liver and other organs leading to smaller accumulated amounts in tumor tissues, particularly via passive targeting. Here we overcome both these challenges by designing nanoparticles that combine the specificity of antibodies with favorable particle biodistribution profiles, while not exceeding the threshold for renal filtration as a combined vehicle. To that end, ultrasmall silica nanoparticles are functionalized with anti-human epidermal growth factor receptor 2 (HER2) single-chain variable fragments to exhibit high tumor-targeting efficiency and efficient renal clearance. This ultrasmall targeted nanotheranostics/nanotherapeutic platform has broad utility, both for imaging a variety of tumor tissues by suitably adopting the targeting fragment and as a potentially useful drug delivery vehicle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Kim, S. E., Zhang, L., Ma, K., Riegman, M., Chen, F., Ingold, I., Conrad, M., Turker, M. Z., Gao, M., Jiang, X., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.164 · Cited by 622
Self-citation
Cited by
Elimination Pathways of Nanoparticles
Poon, W., Zhang, Y.-N., Ouyang, B., Kingston, B. R., Wu, J. L. Y., Wilhelm, S., & Chan, W. C. W. (2019) · ACS Nano · doi:10.1021/acsnano.9b01383 · Cited by 575
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 433
Synthetic amorphous silica nanoparticles: toxicity, biomedical and environmental implications
Croissant, J. G., Butler, K. S., Zink, J. I., & Brinker, C. J. (2020) · Nature Reviews Materials · doi:10.1038/s41578-020-0230-0 · Cited by 424
Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles
Luther, D. C., Huang, R., Jeon, T., Zhang, X., Lee, Y.-W., Nagaraj, H., & Rotello, V. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.020 · Cited by 364
Advancing engineering design strategies for targeted cancer nanomedicine
Gomerdinger, V. F., Nabar, N., & Hammond, P. T. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00847-2 · Cited by 146
Metadata
- Authors
- Chen, F., Ma, K., Madajewski, B., Zhuang, L., Zhang, L., Rickert, K., Marelli, M., Yoo, B., Turker, M. Z., Overholtzer, M., Quinn, T. P., Gonen, M., Zanzonico, P., Tuesca, A., Bowen, M. A., Norton, L., Subramony, J. A., Wiesner, U., & Bradbury, M. S.
- Venue
- Nature Communications
- Published
- 2018-10-08
- Volume
- 9
- Issue
- 1
- Pages
- 4141-4141
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2894805846
- Cited by
- 185
- References
- 3
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. https://app.cochat.ai/papers/10.1038/s41467-018-06271-5
- The paper
- Chen, F., Ma, K., Madajewski, B., Zhuang, L., Zhang, L., Rickert, K., Marelli, M., Yoo, B., Turker, M. Z., Overholtzer, M., Quinn, T. P., Gonen, M., Zanzonico, P., Tuesca, A., Bowen, M. A., Norton, L., Subramony, J. A., Wiesner, U., & Bradbury, M. S. (2018). Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nature Communications. https://doi.org/10.1038/s41467-018-06271-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.